NCT00607607

A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer

A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Recurrent or Resistant Epithelial Ovarian Cancer or Advanced Endometrial Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: CASI Pharmaceuticals, Inc. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients will be treated with MKC-1, twice daily for 14 consecutive days every four weeks (a cycle of MKC-1 chemotherapy), until disease progression or unacceptable toxicities. Patients will be stratified to Arm A (ovarian cancer) or Arm B (endometrial cancer), and will receive identical treatment regimens.

Conditions

• Ovarian Cancer
• Endometrial Cancer

Interventions

Type	Name	Description
DRUG	MKC-1	capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles

Timeline

• Start date: 2008-01-01
• Primary completion: 2011-06-01
• Completion: 2012-01-01
• First posted: 2008-02-06
• Last updated: 2012-01-20

Locations

6 sites across 1 country: Canada